TITLE:
Characterization of Genomic Events Other than Ph and Evaluation of Prognostic Influence on Imatinib in Chronic Myeloid Leukemia (CML): A Study on 1449 Patients from India
AUTHORS:
P. S. Kadam Amare, H. Jain, S. Kabre, D. Walke, H. Menon, M. Sengar, N. Khatri, B. Bagal, U. Dangi, H. Jain, P. G. Subramanian, S. Gujral
KEYWORDS:
CML, ACAs, CCyR, Genomic Deletions, Imatinib
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.4,
April
22,
2016
ABSTRACT: Background: Analysis of Philadelphia (Ph) chromosome, a hallmark of
chronic myeloid leukemia (CML) plays an important role in disease monitoring of
the targeted drug Imatinib. Apart from Ph, genomic imbalances such as
additional chromosomal abnormalities (ACAs) of major route occur during
transformation of the disease and show negative impact on prognosis. Objective:
The present study was carried out to investigate frequencies of ACAs, genomic
deletions, complex Ph variants and their prognostic influences in a large
cohort of newly diagnosed CML-CP (chronic phase) and CML-AP/BP
(accelerated/blast phase). Material & Methods: Retrospective, single
institutional study on 1367 cases of CML-CP and 82 cases of CML-AP/BP between
2009 and 2015, using conventional cytogenetics along with fluorescence in situ hybridization. Results: Of the
1367 patients in CML-CP, 1041 patients who completed 12 - 18 months of Imatinib
therapy showed complete cytogenetic remission (CCyR) rates of 76% and 82% at 12
and 18 months respectively. Imatinib induced 81% and 33% CCyR in CML-AP and
CML-BP respectively. Frequencies of ACAs in CML-CP, AP and BP were 2%, 27% and
67% respectively. Patients in chronic and AP/BP phase with ACAs showed
resistance to Imatinib (p p p